Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.

Authors:
Han Shin Lee
Han Shin Lee
Kangwon National University
South Korea
YoungJoo Lee
YoungJoo Lee
Sejong University
South Korea
Sae Byul Lee
Sae Byul Lee
Asan Medical Center
Guiyun Sohn
Guiyun Sohn
Asan Medical Center
Jisun Kim
Jisun Kim
Korea University
Il Yong Chung
Il Yong Chung
Seoul National University Bundang Hospital
South Korea
Beom Seok Ko
Beom Seok Ko
University of Ulsan College of Medicine

Ann Surg Oncol 2019 Jul 11;26(7):2166-2174. Epub 2019 Apr 11.

Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

Purpose: Mucinous carcinoma (MC) is a rare breast cancer with favorable outcome. Unlike typical breast cancer, the current guidelines do not recommend chemotherapy or anti-human epidermal growth factor receptor 2 (HER2) therapy for hormone receptor (HR)-positive MC, regardless of HER2 status. We evaluated the prognostic implication of HER2 status in HR-positive MC.

Methods: We retrospectively reviewed the data of 471 patients with pure MC (stages I-III) who underwent curative surgery. We analyzed 5-year disease-free survival (DFS) and distant metastasis-free survival (DMFS), according to clinicopathological characteristics.

Results: The median follow-up duration was 79.0 months. Overall, the 5-year DFS rate was 95.7% and the 5-year DMFS rate was 96.2%. Nodal status was the only significant factor for DFS (relative risk [RR], 3.40; 95% confidence interval [CI] 3.40-9.67, p = 0.021). Among HR-positive/node-negative patients with tumor size ≥ 3 cm, HER2-positive patients showed significantly worse DFS (RR, 8.76; 95% CI 1.45-52.76, p = 0.018) and DMFS (RR, 11.37; 95% CI 1.37-74.70, p = 0.011). This finding was consistently significant, when combining both "HR-positive/node-negative/tumor size ≥ 3 cm" and "HR-positive/node-positive" MC (n = 125) for DFS (RR, 4.30; 95% CI 1.43-12.97, p = 0.009) and DMFS (RR, 4.93; 95% CI 1.63-14.90, p = 0.005). Intriguingly, within this subgroup, among HER2-positive tumors, whereas 5-year DFS was 60.2% in patients who did not receive trastuzumab, 100% of those who received trastuzumab were disease free (p = 0.053).

Conclusions: In HR-positive, node-negative MC with tumor size ≥ 3 cm, patients with HER2-positive MC showed worse survival, suggesting a potential role of an anti-HER2 strategy in this subgroup.

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07332-9DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
July 2019
3 Reads

Publication Analysis

Top Keywords

breast cancer
12
her2 status
12
tumor size
8
5-year dfs
8
size ≥ 3 cm
8
implication her2
8
dfs
6
95%
5
patients
5
hr-positive/node-negative patients
4
p = 0021 hr-positive/node-negative
4
interval [ci]
4
95% confidence
4
340 95%
4
confidence interval
4
patients tumor
4
[ci] 340-967
4
340-967 p = 0021
4
≥ 3 cm her2-positive
4
145-5276 p = 0018
4

Altmetric Statistics

References

(Supplied by CrossRef)
Article in Cancer
K Komaki et al.
Cancer 1988
Article in J Surg Oncol
S André et al.
J Surg Oncol 1995
Article in Hormones Cancer
CI Li et al.
Hormones Cancer 2010
Article in J Korean Med Sci
S Park et al.
J Korean Med Sci 2010
Article in Cancer Epidemiol Prevent Biomarkers
WF Anderson et al.
Cancer Epidemiol Prevent Biomarkers 2004
Article in Breast Cancer Res Treat
S Saverio Di et al.
Breast Cancer Res Treat 2008
Article in J Clin Oncol.
SG Diab et al.
J Clin Oncol. 1999
Article in J Breast Cancer
SY Bae et al.
J Breast Cancer 2011
Article in Arch Surg.
SH Ahn et al.
Arch Surg. 2004
Article in Breast Cancer Res Treat
SH Ahn et al.
Breast Cancer Res Treat 2006
Article in Mod Pathol.
DC Allred et al.
Mod Pathol. 1998

Similar Publications